Equity Profile

CELC

Celcuity Inc.

Health CareBiotechnology$4.3B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative treatments for cancer....

Key Metrics to Watch

EPS

Earnings per share is crucial as it reflects the company's profitability and financial health.

$-1.18

Revenue

Revenue figures indicate the company's sales performance and market demand for its products.

$7M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CELC Q2-2026 Earnings Preview

Context

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative treatments for cancer. With a market cap of $4 billion, its work is significant as it aims to improve patient outcomes in the health care sector through targeted therapies.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.76%

Avg Stock Reaction

+1.94%

Last Quarter Recap

In Q1 2026, Celcuity reported an EPS of $-0.86, which was better than the expected $-1.07, leading to a positive stock reaction of 8.23%. However, revenue details were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting a challenging quarter with a consensus EPS of $-1.18, reflecting ongoing investment in research and development. Revenue expectations are set at $7 million, indicating cautious optimism.

Bull Case

If Celcuity can exceed revenue expectations and show a smaller EPS loss than anticipated, it may signal strong demand for its products and effective cost management.

Bear Case

Conversely, if the company reports a wider EPS loss and fails to generate significant revenue, it could raise concerns about its business model and future growth prospects.

Key Metrics to Watch

EPS

$-1.18

Earnings per share is crucial as it reflects the company's profitability and financial health.

Revenue

$7M

Revenue figures indicate the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the reported EPS be better than the consensus estimate of $-1.18?

A smaller loss than expected could indicate improved operational efficiency and investor confidence.

What is the actual revenue figure compared to the consensus of $7 million?

Revenue performance is critical for assessing market demand and the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Celcuity's potential for revenue growth given its recent positive EPS surprises, which suggest operational improvements.

Supporting Evidence

The company has consistently beaten EPS estimates in recent quarters, indicating stronger-than-expected performance.

The options market is pricing a larger move than historical averages, suggesting that investors may be overly cautious.

Recent trends in biotech suggest a rebound in investor sentiment, which could benefit Celcuity.

Key Risk

If revenue significantly exceeds $10 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Celcuity can sustain its growth trajectory amidst ongoing investments.

Bull Confirmed If

An EPS loss of less than $-1.10 combined with revenue exceeding $10 million would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-1.25 and revenue below $5 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.47%

Historical Avg

±4.1%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±12.5% while CELC has averaged ±4.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

73.5%

Calls (79K)P/C Ratio: 0.54Puts (54K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celcuity beats expectations, history suggests an average stock move of +3.4%, reinforcing confidence in its growth strategy.

In-Line / Cautious

A report in line with expectations may lead to a muted reaction as investors await further clarity on future guidance.

Miss

Should the company miss expectations, history indicates a potential decline of around -2.4%, raising concerns about its operational effectiveness.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug trials or partnerships that could impact revenue.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for Celcuity's products.
4Guidance on future revenue expectations beyond this quarter.
5Responses to competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ePlus inc.

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative treatments for cancer....

Key Metrics to Watch

EPS

Earnings per share is crucial as it reflects the company's profitability and financial health.

$-1.18

Revenue

Revenue figures indicate the company's sales performance and market demand for its products.

$7M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CELC Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.76%

Avg Stock Reaction

+1.94%

Last Quarter Recap

In Q1 2026, Celcuity reported an EPS of $-0.86, which was better than the expected $-1.07, leading to a positive stock reaction of 8.23%. However, revenue details were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Celcuity can exceed revenue expectations and show a smaller EPS loss than anticipated, it may signal strong demand for its products and effective cost management.

Bear Case

Conversely, if the company reports a wider EPS loss and fails to generate significant revenue, it could raise concerns about its business model and future growth prospects.

Key Metrics to Watch

EPS

$-1.18

Earnings per share is crucial as it reflects the company's profitability and financial health.

Revenue

$7M

Revenue figures indicate the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the reported EPS be better than the consensus estimate of $-1.18?

A smaller loss than expected could indicate improved operational efficiency and investor confidence.

What is the actual revenue figure compared to the consensus of $7 million?

Revenue performance is critical for assessing market demand and the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Celcuity's potential for revenue growth given its recent positive EPS surprises, which suggest operational improvements.

Supporting Evidence

The company has consistently beaten EPS estimates in recent quarters, indicating stronger-than-expected performance.

The options market is pricing a larger move than historical averages, suggesting that investors may be overly cautious.

Recent trends in biotech suggest a rebound in investor sentiment, which could benefit Celcuity.

Key Risk

If revenue significantly exceeds $10 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Celcuity can sustain its growth trajectory amidst ongoing investments.

Bull Confirmed If

An EPS loss of less than $-1.10 combined with revenue exceeding $10 million would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-1.25 and revenue below $5 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.47%

Historical Avg

±4.1%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±12.5% while CELC has averaged ±4.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

73.5%

Calls (79K)P/C Ratio: 0.54Puts (54K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celcuity beats expectations, history suggests an average stock move of +3.4%, reinforcing confidence in its growth strategy.

In-Line / Cautious

A report in line with expectations may lead to a muted reaction as investors await further clarity on future guidance.

Miss

Should the company miss expectations, history indicates a potential decline of around -2.4%, raising concerns about its operational effectiveness.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug trials or partnerships that could impact revenue.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for Celcuity's products.
4Guidance on future revenue expectations beyond this quarter.
5Responses to competitive pressures in the biotechnology sector.